The claim that isotretinoin permanently clears acne in 85% of patients needs clarification: that 85% figure represents near-complete clearance *during the treatment course itself*, typically within 16 weeks. However, the more clinically relevant statistic is that approximately 61% of patients experience lasting, permanent acne clearance after completing one course of treatment.
The remaining patients experience relapse within 18 months, with roughly 23% ultimately requiring a second course of isotretinoin to achieve long-term control. This distinction between short-term treatment response and durable long-term clearance is critical for anyone considering this medication. Understanding what isotretinoin actually delivers—rather than marketing claims—helps patients make informed decisions about this powerful but demanding acne treatment.
Table of Contents
- What Does the 85% Clearance Rate Actually Mean?
- The Difference Between Short-Term Success and Long-Term Cure
- Why Some Patients Need a Second Course
- How Cumulative Dose Impacts Permanent Clearance
- The Hidden Burden: Monitoring and Side Effects
- Who Becomes a Candidate for Isotretinoin?
- Current Research and Looking Forward
- Conclusion
- Frequently Asked Questions
What Does the 85% Clearance Rate Actually Mean?
The 85% clearance rate cited in acne research refers to patients receiving standard doses of 0.5 to 1.0 mg/kg per day who achieve near-complete or complete clearance of their acne lesions within 16 weeks of treatment. This is a remarkable short-term outcome: by the time most patients finish their isotretinoin course, the vast majority see their skin dramatically improve. The remaining 15% of patients take longer—13% require 5 to 6 months to clear, while 3% need even longer periods. For someone with severe cystic acne that has scarred their face and destroyed their confidence, seeing that kind of rapid improvement is transformative.
However, achieving clearance *during treatment* is different from achieving permanent clearance *after treatment ends*. The critical reality that gets lost in headlines is that isotretinoin’s effect doesn’t always stick permanently. Of that 85% who clear during treatment, only about 61% maintain clear or near-clear skin long-term after stopping the medication. This means roughly 39% of all isotretinoin-treated patients experience some degree of acne relapse within 18 months of completing their course—though “relapse” ranges from minor breakouts to return of moderate or severe acne, depending on the individual and their specific skin biology.
The Difference Between Short-Term Success and Long-Term Cure
Isotretinoin works through a mechanism that appears to permanently reduce sebaceous gland size and sebum production, which should theoretically mean permanent improvement. However, in practice, sebaceous glands can gradually recover function after treatment ends, allowing some patients to develop acne again. This is not a failure of the medication but rather a biological reality: isotretinoin can achieve clinical cure in the majority of cases, but biology doesn’t always cooperate with a permanent cure.
A patient might complete isotretinoin with completely clear skin, only to notice first a few whiteheads after 6 months, then gradually escalating breakouts by month 18. The psychological impact of this relapse can be severe—patients may feel like they’ve failed the treatment or that they’ve wasted months of side effects for nothing, when in fact the medication worked exactly as the statistics suggest it would. One important limitation to understand: the long-term relapse rates vary significantly based on cumulative dose and individual factors. This is where dosage becomes crucial—not just for safety, but for durable outcomes.
Why Some Patients Need a Second Course
Approximately 23% of isotretinoin patients require a second course of treatment, not the 20% mentioned in some headlines. These patients fall into two categories: those who relapsed after initial clearance, and those who experienced incomplete clearance on the first course and never made it to the threshold of near-complete remission. For someone who experiences relapse, the decision to pursue a second course is complicated. It means months of additional checkpoint visits, blood tests, contraception requirements (for women), and potential side effects.
Yet clinical data supports that a second course often achieves better long-term outcomes than a first course, likely because higher cumulative doses correlate with lower relapse rates. The frustration for these patients is real: they’ve already committed to a demanding treatment, seen initial results, and now face doing it all over again. The outcome for second-course patients is generally positive—most achieve durable clearance after their second treatment cycle. However, a tiny fraction of patients may require a third course, though this is rare and usually reserved for severe relapse or incomplete initial responses.
How Cumulative Dose Impacts Permanent Clearance
The relationship between isotretinoin dose and relapse risk is striking and often underappreciated by patients. Patients receiving a high cumulative dose of isotretinoin (≥220 mg/kg total) have a relapse rate of only 26.9%. By contrast, patients receiving a low cumulative dose (<220 mg/kg total) have a relapse rate of 47.4%—nearly double the risk. This has real clinical implications: a patient who completes isotretinoin with a cumulative dose of 180 mg/kg has almost a coin-flip chance of relapsing, whereas someone reaching 240 mg/kg or higher has a much stronger probability of durable clearance.
The tradeoff is that higher cumulative doses also increase the risk of side effects, particularly elevated cholesterol, liver enzyme changes, and joint discomfort. This creates a clinical balancing act: dermatologists must weigh the benefit of a more robust long-term outcome against the increased side effect burden. For patients, this means that if your dermatologist recommends a higher dose or a longer treatment course, there’s solid science behind that recommendation. A lower dose might feel like it’s clearing your skin just fine, but statistically, you’re running nearly twice the relapse risk compared to someone on a higher cumulative dose.
The Hidden Burden: Monitoring and Side Effects
While isotretinoin’s clearance rates are impressive, the treatment process itself is demanding in ways that go beyond the acne itself. The medication requires monthly check-ins with blood work to monitor liver function and lipid panels. Women of childbearing age must enroll in the iPLEDGE program and use two forms of contraception, since isotretinoin is profoundly teratogenic—exposure during pregnancy causes severe birth defects. This administrative and contraceptive burden falls entirely on female patients, which influences who pursues this treatment and who doesn’t. Beyond lab monitoring, most patients experience dry skin, dry lips, and often joint or muscle discomfort.
Some experience mood changes, and while a causal relationship with depression and suicide remains controversial, the FDA maintains a black-box warning. These side effects are temporary and reversible, but they persist for the entire duration of treatment—typically 4 to 6 months. A critical limitation many patients don’t appreciate: isotretinoin won’t work well if your acne is driven primarily by factors other than sebum production. Acne triggered mainly by hormonal fluctuation, bacterial resistance, or specific food sensitivities may improve with isotretinoin but might not clear completely. If your acne is related to PCOS (polycystic ovary syndrome) or hormonal imbalance, isotretinoin is still worth considering, but you should discuss expectations with your dermatologist, as outcomes can be less dramatic.
Who Becomes a Candidate for Isotretinoin?
Isotretinoin is typically reserved for severe acne that hasn’t responded to conventional treatments because of the medication’s side effect profile and monitoring requirements. This includes severe nodulocystic acne, acne that’s causing significant scarring, or acne that’s emotionally debilitating. A 22-year-old with moderate acne that could potentially respond to oral antibiotics and retinoids would not typically be offered isotretinoin as a first choice—the side effects and administrative burden wouldn’t be justified. However, that same person with severe cystic acne covering their back and chest, causing permanent scars, and creating social withdrawal, is an ideal candidate.
The FDA doesn’t have a strict acne severity score that automatically qualifies someone for isotretinoin, so the decision is somewhat subjective and depends on your dermatologist’s judgment and your own preferences about treatment burden. Patient age can influence decisions too. A teenager with severe acne has decades of potential relapse to consider, making the higher cumulative dose approach more attractive. An adult in their 30s with late-onset severe acne might accept slightly higher relapse risk in exchange for lower total side effect burden, especially if they’re willing to restart treatment if needed.
Current Research and Looking Forward
Recent dermatological research continues to refine isotretinoin protocols to maximize durable outcomes while minimizing side effects. Some researchers are exploring whether extended low-dose isotretinoin—taking lower doses for longer periods—might achieve the same long-term clearance rates as standard-dose courses. Other work focuses on identifying which patient characteristics predict durable remission versus relapse, so that treatment can be tailored.
The reality is that isotretinoin remains the only medication with the potential to produce durable, long-term acne remission—no other acne treatment offers comparable outcomes. As long as genetic factors predisposing people to acne remain unchanged, isotretinoin will likely remain central to severe acne management. The increasing availability of at-home dermatology consultations and digital monitoring platforms has made accessing isotretinoin somewhat easier in recent years, though it remains appropriately restricted and requires in-person dermatology care.
Conclusion
Isotretinoin delivers remarkable results: 85% of patients achieve near-complete acne clearance within 16 weeks of treatment, and approximately 61% maintain durable, long-term clearance after completing one course. However, roughly 39% of treated patients experience acne relapse within 18 months, with about 23% eventually requiring a second course of treatment. The wide range in individual outcomes—from permanent cure to eventual relapse—is driven by factors including cumulative dose received, individual skin biology, and underlying causes of the acne.
For patients with severe, scarring acne that hasn’t responded to conventional treatments, isotretinoin remains the most effective option available, despite its side effects and monitoring requirements. If you’re considering isotretinoin, work with your dermatologist to understand your individual risk factors for relapse and to determine whether a treatment protocol emphasizing higher cumulative dose makes sense for your situation. Ask specifically about what “clear skin” means—is it complete clearance, or residual mild acne? Clarify expectations around relapse risk and whether a second course would be an option if needed. Having realistic expectations about both the remarkable short-term clearance rates and the more modest long-term permanent clearance statistics will help you make a decision you won’t regret.
Frequently Asked Questions
Does isotretinoin permanently cure acne?
Isotretinoin produces durable long-term clearance in about 61% of patients after one course, with an additional 23% eventually needing a second course. So while it’s the closest thing to a permanent cure that currently exists, complete permanent cure without any possibility of relapse isn’t guaranteed. Higher cumulative doses increase the probability of durable clearance.
How long does isotretinoin treatment take?
Most patients complete isotretinoin in 4 to 6 months. However, some patients take longer to reach full clearance—about 13% require 5 to 6 months, and 3% require even longer. Your dermatologist will continue treatment until you reach near-complete clearance or reach the target cumulative dose, whichever comes first.
What if my acne comes back after isotretinoin?
About 39% of patients experience some degree of relapse within 18 months. If relapse occurs, a second course of isotretinoin is usually offered and typically achieves better long-term outcomes than the first course. Some patients with minor relapse may manage with other topical or oral treatments instead of repeating isotretinoin.
Is a higher dose of isotretinoin better?
Higher cumulative doses correlate with lower relapse rates—patients on ≥220 mg/kg cumulative dose have a 26.9% relapse rate, while those on <220 mg/kg have a 47.4% relapse rate. However, higher doses also increase side effects. Your dermatologist will recommend a dose that balances durable clearance with acceptable side effect risk.
Can I stop isotretinoin early if my acne clears?
No—isotretinoin requires reaching a target cumulative dose, typically 120-150 mg/kg, to achieve the best long-term outcomes. Stopping early before reaching this cumulative dose significantly increases relapse risk. Your dermatologist will not discontinue treatment based on clearance alone.
What happens if isotretinoin doesn’t fully clear my acne?
About 15% of patients require longer than 16 weeks to achieve near-complete clearance. If you’re in this group, your dermatologist will extend your treatment course. Very rarely, a patient may not respond adequately to isotretinoin, which may indicate that other factors (such as hormonal acne or rosacea) are contributing to skin symptoms.
